Biogen, facing declines in sales of older drugs, has a lot riding on its newly approved Alzheimer’s disease treatment.
The company recently announced moves to cut costs and favor investments in innovation and new product launches.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,